Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Clinical Practice Guidelines – Chronic Lymphocytic Leukaemia

Chronic Lymphocytic Leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Published in 2020 – Ann Oncol (2020)
Authors: B. Eichhorst, T. Robak, E. Montserrat, P. Ghia, C. U. Niemann, A. P. Kater, M. Gregor, F. Cymbalista, C. Buske, P. Hillmen, M. Hallek & U. Mey, on behalf of the ESMO Guidelines Committee

  • These updated ESMO Clinical Practice Guidelines provide key recommendations on the management of chronic lymphocytic leukaemia (CLL)
  • Authorship includes a multidisciplinary group of experts from different institutions and countries in Europe
  • Recommendations are provided, including levels of evidence and grades of recommendation where applicable
  • Prognosis and treatment decisions in CLL depend on genetic and clinical factors including age, stage and comorbidities
  • Therapies targeting B-cell-receptor pathway or defect mechanism of apoptosis induce long lasting remissions

These Clinical Practice Guidelines are endorsed by the European Hematology Association (EHA) through the Scientific Working Group on CLL/European Research Initiative on CLL (ERIC).

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings